Prostate Cancer Management: Future Directions in Care
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Read More
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Read More
Addressing Bone and Visceral Metastases in Metastatic CRPC
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Read More
Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
Read More
Selecting Among Novel Imaging Options in Metastatic CRPC
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Read More
Metastatic CRPC: Utility of Imaging as a Biomarker
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
Read More
DNA Alterations and Selection of PARP Inhibitors in mCRPC
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Read More
Overview of Therapy for mCRPC: PARP Inhibitors
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Read More
Interpreting Data From the ARASENS Trial in Metastatic HSPC
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Read More
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Read More
Role of Micronized Abiraterone in Metastatic HSPC
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
Read More
Overview of Treatment for Metastatic HSPC
Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
Read More
Monitoring Strategies in Nonmetastatic CRPC
A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
Read More
Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Read More
Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Read More
Evolving Treatment Landscape of Nonmetastatic CRPC
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Read More
Dr. Yu on Future Directions in Prostate Cancer
July 25th 2019Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.
Read More
Dr. Yu on Initial Findings From the KEYNOTE-365 Trial in mCRPC
July 19th 2019Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses initial findings from the KEYNOTE-365 trial in metastatic castration resistant prostate cancer mCRPC).
Read More
Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC
June 21st 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.
Read More
Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer
February 23rd 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.
Read More
Dr. Yu on Combination Therapy for Patients With Metastatic Prostate Cancer
February 14th 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.
Read More
Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
June 25th 2018Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.
Read More
Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer
June 6th 2018Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.
Read More
Dr. Yu Discusses Optimal Testosterone Suppression
February 6th 2014Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.
Read More